Shanghai Labway Clinical Laboratory Co

Shanghai Labway Clinical Laboratory Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Shanghai Labway Clinical Laboratory Co (301060.SZ) as of Nov 2, 2026 is -684.19 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -127.65 % — a change of 435.98% (lower).

FCF Conversion

-684.19 %

YoY

435.98%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Shanghai Labway Clinical Laboratory Co is 2025 -684.19 % . FCF Conversion Rate (FCF/EBITDA) of Shanghai Labway Clinical Laboratory Co was 2024 -127.65 % . It decreases by 435.98% lower compared to the previous year.

The Shanghai Labway Clinical Laboratory Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
151.87 CNY
Jan 1, 2019
33.70 CNY
Jan 1, 2020
111.73 CNY
Jan 1, 2021
51.33 CNY
Jan 1, 2022
-23.64 CNY
Jan 1, 2023
-104.60 CNY
Jan 1, 2024
-127.65 CNY
Jan 1, 2025
-684.19 CNY
The Shanghai Labway Clinical Laboratory Co FCF Conversion history
YEARFCF ConversionYoY
-684.19 %+435.98%
-127.65 %+22.04%
-104.60 %+342.54%
-23.64 %-146.05%
51.33 %-54.06%
111.73 %+231.51%
33.70 %-77.81%
151.87 %-104.31%
-3,523.05 %+2,620.15%
-129.52 %-386.19%
45.26 %-132.59%
-138.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Shanghai Labway Clinical Laboratory Co Stock analysis

What does Shanghai Labway Clinical Laboratory Co do? Shanghai Labway Clinical Laboratory Co., Ltd. generates revenue through medical and pathological examination services, including pathological diagnosis, molecular examination, biochemical examination, immune examination, microbial examination, clinical basic examination, and physical and chemical examination. The company also sells in vitro diagnostic instruments, reagents, and related accessories and consumables. Its primary customers are healthcare providers and medical institutions requiring diagnostic services and diagnostic products. The business segments are medical testing services and in vitro diagnostic product sales. The company's medical testing services cater to hospitals and clinics seeking comprehensive diagnostic solutions, while the in vitro diagnostic product sales target healthcare facilities needing equipment and supplies for laboratory operations. These services and products are provided to clients across China, focusing on the healthcare sector's demand for accurate and timely diagnostic capabilities. Shanghai Labway's revenue streams are derived from both service fees for examinations and sales of diagnostic instruments and reagents. The company's offerings align with the growing need for advanced medical diagnostics in China's expanding healthcare market, serving a broad client base within the medical industry. Shanghai Labway Clinical Laboratory Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Labway Clinical Laboratory Co stock

FCF Conversion Rate (FCF/EBITDA) of Shanghai Labway Clinical Laboratory Co is -684.19 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Shanghai Labway Clinical Laboratory Co changed from -127.65 % to -684.19 %, representing a 435.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Shanghai Labway Clinical Laboratory Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Shanghai Labway Clinical Laboratory Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Shanghai Labway Clinical Laboratory Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Shanghai Labway Clinical Laboratory Co